key: cord-0746269-quvntajb
authors: Ozdem, Sadi S.
title: An overview of non-clinical safety studies in current Turkish regulations for the development of COVID-19 vaccines
date: 2022-01-14
journal: Biologicals
DOI: 10.1016/j.biologicals.2022.01.006
sha: 4acf2b24055e041043555548526d6a50fe615760
doc_id: 746269
cord_uid: quvntajb

nan

In conclusion, compliance with global guidances decreases inter-regional 113 differences in nonclinical safety requirements, promotes the timely conduct of clinical 114 trials, decreases overall development costs, and reduces animal use according to the 115 3Rs: initiative of reduce, refine, and replace [14, 18, 19] 

WHO declares COVID-19 a pandemic

World Health Organisation. COVID-19 vaccine tracker and landscape

Türkiye İlaç ve Tıbbi Cihaz Kurumu

Global Regulatory Guidelines for Vaccines

Nonclinical Safety Evaluation of Drugs

Toxicologic Pathology

Species selection considerations for preclinical toxicology studies for 188 biotherapeutics

Regulatory Guidelines and Their Application in the 190

PLitnick LM, Herzyk DJ

Nonclinical Safety Assessment of Vaccines and 195

Vaccine Adjuvants

To 3R is humane

on the protection of animals used for scientific purposes